+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 140 Actively Recruiting clinical trials

S

Actively Recruiting

Chronic kidney disease CKD affects over 800 million people worldwide and leads to significant health challenges, including multiple secondary diseases, frequent hospital visits, and high costs. Recent advances have identified promising drugs like sodium-glucose co-transporter 2 inhibitors, finerenone, and semaglutide that may slow CKD progression. This study aims to evaluate whether a biomarker-guided treatment approach can better reduce kidney function decline compared to standard care in CKD patients with albuminuria. This prospective, randomized, open-label study plans to enroll 125 participants with CKD and albuminuria who will be randomly assigned to either a biomarker-targeted treatment group or a standard care group. In the treatment group, medications such as dapagliflozin, finerenone, and semaglutide will be added stepwise based on urinary biomarkers UACR and UEGF and individual response. After about four weeks on each drugs maximum tolerated dose, biomarker levels will be reassessed to decide whether to continue, switch, or add treatments. Participants will undergo regular evaluations of kidney function through estimated glomerular filtration rate eGFR and urinary biomarkers throughout the study, which lasts over two years. The main outcome measured is the change in eGFR slope from week 26 to week 104. Additional assessments include changes in eGFR and UACR from baseline to week 104 or 112. Safety and effectiveness of the biomarker-guided approach will be monitored carefully during the trial.

Age: 18Years - 75YearsAll GendersPhase 4
4 locations
E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
E

Actively Recruiting

Cardiovascular disease CVD is a leading cause of death worldwide and unhealthy lifestyle behaviors are well-known risk factors. This study evaluates whether a digital lifestyle intervention developed within Swedish primary healthcare can improve important cardiovascular health outcomes and promote healthier lifestyle behaviors in patients aged 40 to 60 years. Participants are recruited from multiple centers in Sweden and randomized to either the intervention or control group with standard care. Participants in the intervention group receive support through a digital lifestyle program that includes lectures, home assignments, and group meetings, along with personalized digital feedback from healthcare providers. Both groups receive standard care, which is one structured health dialogue focused on lifestyle habits. The study measures outcomes at 6 months post-randomization, including LDL-cholesterol as the primary outcome, and several secondary outcomes related to cholesterol levels, blood glucose, blood pressure, weight, lifestyle behaviors, and quality of life. Throughout the study, participants undergo assessments of blood lipids, glucose, blood pressure, body measurements, and lifestyle factors such as diet, physical activity, sleep, stress, alcohol, and tobacco use. Researchers also evaluate cardiovascular risk scores and collect participant feedback on using the digital intervention. The total study duration is 6 months post-randomization with data collected to assess the impact of the digital program compared to standard care.

Age: 39Years - 61YearsAll GendersPhase Not Applicable
6 locations
F

Actively Recruiting

Healthy Volunteer

Opioid overdose causes significant global health problems, and while prevention and treatment programs exist, more efforts are needed to reduce deaths and complications. This research evaluates a novel smartphone-based volunteer first responder system integrated with national emergency call services to assist suspected opioid overdoses. The system aims to alert trained volunteers equipped with naloxone, an opioid antidote, to provide early treatment before emergency medical services arrive, potentially saving lives by reducing the time to naloxone administration. Volunteer responders, called naloxone-responders, will complete training in opioid overdose recognition, naloxone use, and first aid based on European and Swedish guidelines. They will also learn low-arousal communication techniques for interacting with overdose victims. Each responder receives a kit with two doses of nasal naloxone and will be registered on a dedicated responder smartphone app. The study includes a two-year pilot phase with one-year follow-up per participant, along with multiple sub-studies examining feasibility, safety, acceptability, mortality, and experiences of responders and overdose survivors. Participants will be monitored through questionnaires, app data, and medical records from dispatchers, paramedics, and hospitals. The primary outcomes include the number of successful naloxone responder alerts, responder acceptability, clinical outcomes of overdose victims, and safety experiences during alerts. Mortality rates before and after the trial will also be analyzed. The study runs from September 2025 to August 2027, assessing both short- and long-term effects of integrating volunteer responders with emergency medical dispatch.

Age: 18Years +All GendersPhase Not Applicable
1 location
W

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a behavioural intervention called Light, activity and sleep in my daily life LAS aimed at improving quality of life for community-dwelling older adults aged 70 and over. The study focuses on addressing challenges related to circadian rhythm sleep disorders, poor sleep, reduced physical activity, and time spent indoors, which affect wellbeing in this population. The intervention targets light-related behaviour, outdoor walking, and sleep routines to promote active ageing and independence. The LAS intervention is delivered as a 9-week web-based course with nine modules covering electric lighting, daylight, outdoor physical activity, and sleep. Participants also receive a test kit with items like light bulbs, a sleep mask, and a sleep diary to support engagement and experimentation. The course includes one introductory physical meeting and three additional meetings held at a senior citizen meeting point. All participants receive the same noninvasive behavioural education and support. Participants complete questionnaires, interviews, and wear accelerometers to track activity and rest patterns before and after the course, with follow-ups at 3, 6, and 10 months after baseline. Outcomes measured include usability of the intervention, mood, sleep quality, behavioural skills, quality of life, physical activity, sedentary behaviour, and step counts. The study also explores factors that help or hinder daytime outdoor walking. Results will guide improvements for future delivery within municipal health promotion services.

Age: 70Years +All GendersPhase Not Applicable
4 locations
C

Actively Recruiting

Researchers are evaluating two different weekly doses of Alpha1-Proteinase Inhibitor Alpha1-PI given by injection under the skin compared with the standard intravenous doses in adults with Alpha-1 Antitrypsin Deficiency. This Phase 3, open-label study aims to understand how the body processes the medicine and to assess the safety and tolerability of the different doses. Participants are randomly assigned to treatment groups in a parallel design, with both doctors and participants aware of the assigned treatment. Participants undergo two treatment periods the first with intravenous IV Liquid Alpha1-PI given weekly at either 60 mgkg or 120 mgkg for 8 weeks, followed by a second period with subcutaneous SC Alpha1-PI 15% injection at corresponding higher doses 90 mgkg or 180 mgkg also given weekly for 8 weeks. Participants receive each dosing schedule sequentially to compare pharmacokinetics and safety between IV and SC administration. During the study, participants have regular visits to monitor steady-state levels of Alpha1-PI in the blood, lung function tests, and safety assessments. Key measurements include the area under the curve AUC of Alpha1-PI over each weekly interval and trough serum levels at specific weeks. The study includes screening, 16 weeks of treatment divided into two 8-week periods, and ongoing safety and tolerability evaluations throughout.

Age: 18Years - 80YearsAll GendersPhase 3
22 locations
S

Actively Recruiting

Researchers are evaluating the Attempted Suicide Short Intervention Program ASSIP to prevent future suicidal behavior in people who have recently attempted suicide. This multicenter, randomized controlled trial in Sweden aims to compare ASSIP as a supplement to usual psychiatric care versus usual care alone. The study also explores factors that may influence ASSIPs effectiveness and assesses its cost-effectiveness. Participants receive either ASSIP plus standard treatment or standard treatment alone. ASSIP involves up to four therapy sessions, including a videotaped narrative interview, video playback with discussion, development of a personalized prevention plan, and an optional mini-exposure session. Therapists also send standardized letters to participants over two years to maintain contact. Standard treatment includes multidisciplinary care such as psychotherapy, medication, and referrals to specialist or primary care as needed. Participants undergo baseline interviews and self-assessments, followed by telephone interviews and self-assessment scales at 3, 12, and 24 months. Researchers collect data from medical records, national health and social insurance registers, and track suicide attempts and health outcomes over two years. The primary outcomes include the number of suicide attempts and cost-effectiveness over this period, with secondary measures covering suicidal thoughts, quality of life, healthcare use, and employment status.

Age: 18Years +All GendersPhase Not Applicable
2 locations
R

Actively Recruiting

Researchers are investigating whether regular radiological assessments during follow-up after surgery for high-risk malignant melanoma improve patient survival. The study addresses concerns about the resource demands, potential radiation exposure, and anxiety caused by such imaging, especially given the recent introduction of effective medical treatments for melanoma. There is currently no clear evidence supporting routine imaging in this context. Participants are randomly assigned to one of two groups. One group follows national guidelines with regular doctor appointments for 3 years, while the other group receives the same follow-up plus additional whole-body CT or PET scans and blood tests at baseline, 6, 12, 24, and 36 months. An interim analysis will be done after 1,000 patients enroll. During the study, researchers will monitor overall survival at 5 years as the primary outcome. They will also assess quality of life through questionnaires over the 3-year follow-up. Participants will attend scheduled visits for clinical evaluations, imaging, and blood tests, with the study aiming to provide clear evidence about the role of imaging in post-surgical melanoma care.

Age: 18Years +All GendersPhase Not Applicable
20 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating how different doses of a study medicine called Inno8 work in the bodies of people with haemophilia A. The purpose is to see if Inno8 is safe for use in this condition. This is a phase 1 treatment study sponsored by Novo Nordisk AS, lasting about 11 weeks, involving adult males with haemophilia A. Participants will receive oral doses of the study drug NNC0442-0344 A across three experimental cohorts. The dosing will be monitored closely throughout the study period. The study is designed as a single-group, non-randomized trial without blinding. During the study, participants will be evaluated for side effects and blood markers related to coagulation, such as D-dimer, prothrombin fragments, fibrinogen, and platelets. Researchers will also measure drug concentration levels and immune response indicators from the first dose through to the end of follow-up at Day 46. Safety assessments will be ongoing to monitor adverse events during the treatment and follow-up period.

Age: 18Years - 64YearsMALEPhase 1
33 locations

1-10 of 140

1